INOVIQ owns or licences the proprietary SubB2M™, NETs, BARD1 and hTERT technologies that have multiple potential diagnostic and therapeutic applications.

INOVIQ has commercialised two products including the hTERT test for use as an adjunct to urine cytology testing for bladder cancer and the EXO-NET^® pan-exosome capture tool for research purposes.

INOVIQ is developing a multi-product diagnostic and exosome-based pipeline focused on the detection and monitoring of cancer and other diseases to improve patient health outcomes.